Jubilant Pharmova subsidiary gets US FDA note for Washington unit
Following an audit conducted from May 28-June 6, 2024, the US FDA has classified the drug firm's Spokane, Washington, manufacturing facility's inspection status as 'voluntary action indicated' (VAI). Shares of Jubilant Pharmova Ltd ended at ₹1,014.10, down by ₹16.30, or 1.58%, on the BSE.
BSE
JUBLPHARMA
General
Markets